The initial phase includes NewGen’s expansion into the UAE, with subsequent growth initiatives planned.

BANGKOK, April 03, 2025 — NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), an Asian fertility services provider assisting couples and individuals in accessing fertility treatments, announced it has secured $5.2 million in strategic funding through two agreements with an investor (the “investor”). The arrangements could potentially raise a total of up to $30.8 million. This funding will enable NewGen to pursue key growth strategies, including establishing a cutting-edge fertility clinic in Dubai, United Arab Emirates.

On April 2, 2025, the Company completed the fourth tranche of its debt financing, as outlined in the existing Securities Purchase Agreement with the investor, initially disclosed in a 6-K filing with the SEC on August 16, 2024. At the closing of the fourth tranche, the Company sold to the investor a senior convertible note with a principal amount of $2,000,000. The note carries an annual interest rate of 14.75%, which may be adjusted according to its terms.

On April 1, 2025, the Company entered into a new Securities Purchase Agreement with the investor, agreeing to sell a senior convertible note with an aggregate original principal amount not exceeding $3,200,000. The Company may request the investor to participate in selling additional convertible notes, with the total original principal amount for all additional notes not exceeding $25,600,000.

Further details regarding these arrangements are available in NewGen’s 6-K filing with the SEC on April 3, 2025.

The funds will support the establishment of a fertility clinic in Dubai, utilizing NewGen’s recently acquired exclusive Microsort technology. This will provide a strong operational foundation in the region. The UAE’s regulatory framework allows for comprehensive fertility services, including IVF with gender selection, egg donation, and surrogacy. The clinic will cater to patients from the UAE, European Union residents seeking advanced treatments, and those from neighboring regions, particularly India, where family balancing services are in high demand. Dubai’s position as a global travel hub makes it ideal for international patients seeking top-tier fertility care. Construction is expected to begin in the second quarter, with the opening planned for the fourth quarter of this year.

Mr. Siu Wing Fung Alfred, Founder, Chairman, and CEO of NewGen, stated, “This funding is a major step in our global expansion and provides the necessary capital for long-term growth. The UAE’s favorable regulatory environment allows us to offer a complete range of services, making it perfect for our next expansion phase. By leveraging our Microsort technology, we aim to establish a strong presence in Dubai, serving as a hub for patients from various regions. This represents a crucial step in our dedication to providing world-class fertility solutions to patients worldwide.”

About NewGen
NewGen provides comprehensive fertility services in Asia, helping couples and individuals access fertility treatments. With a mission to help individuals and couples build families, NewGen focuses on improving access to infertility treatment and delivering comprehensive fertility services. The NewGen management team has over a decade of combined experience in the fertility industry. NewGen clinics are located in Thailand, Cambodia, and Kyrgyzstan, offering a complete suite of services, including infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, where permitted. More information is available at [website address]. The information on NewGen’s website is not incorporated into this press release.

Forward-Looking Statements
This release contains forward-looking statements made under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are generally identified by terms like “believe,” “project,” “expect,” and similar expressions. These statements include descriptions of the Company’s future commercial operations, investments, business strategy, and financial condition. Forward-looking statements involve predictions about future events based on current expectations and assumptions, making them subject to risks and uncertainties. Various factors could cause actual events to differ materially from these statements, including the Company’s ability to establish a clinic in Dubai, attract international customers, or the regulatory and competitive environment. Readers should carefully consider these factors and other risks detailed in the Company’s annual report on Form 20-F and other SEC filings, which could cause actual results to differ materially. These documents are available on the SEC’s website, www.sec.gov. All information is current as of the release date, and the Company does not undertake to update any forward-looking statement, except as legally required.

Investor Relations Contact
ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: 

“`